A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis

NCT00035529 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Placebo
DRUG: BMS 188667 (Abatacept)
DRUG: BMS 188667 (Abatacept)

Sponsor

Bristol-Myers Squibb